ACADIA Pharmaceuticals Inc. (ACAD): Price and Financial Metrics

ACADIA Pharmaceuticals Inc. (ACAD): $17.19

0.34 (+2.02%)

POWR Rating

Component Grades














  • ACAD scores best on the Quality dimension, with a Quality rank ahead of 87.86% of US stocks.
  • The strongest trend for ACAD is in Stability, which has been heading down over the past 179 days.
  • ACAD ranks lowest in Stability; there it ranks in the 19th percentile.

ACAD Stock Summary

  • The ratio of debt to operating expenses for ACADIA PHARMACEUTICALS INC is higher than it is for about just 13.37% of US stocks.
  • With a price/sales ratio of 5.09, ACADIA PHARMACEUTICALS INC has a higher such ratio than 76.95% of stocks in our set.
  • ACAD's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 19.44% of US stocks.
  • If you're looking for stocks that are quantitatively similar to ACADIA PHARMACEUTICALS INC, a group of peers worth examining would be ARDX, IVAC, DAIO, GANX, and GTHX.
  • Visit ACAD's SEC page to see the company's official filings. To visit the company's web site, go to

ACAD Valuation Summary

  • In comparison to the median Healthcare stock, ACAD's price/earnings ratio is 161.86% lower, now standing at -13.3.
  • ACAD's price/sales ratio has moved down 12.2 over the prior 222 months.

Below are key valuation metrics over time for ACAD.

Stock Date P/S P/B P/E EV/EBIT
ACAD 2022-09-01 5.3 6.3 -13.3 -12.9
ACAD 2022-08-31 5.2 6.1 -13.0 -12.6
ACAD 2022-08-30 5.1 6.0 -12.8 -12.4
ACAD 2022-08-29 5.2 6.1 -13.0 -12.6
ACAD 2022-08-26 5.2 6.2 -13.1 -12.7
ACAD 2022-08-25 5.3 6.3 -13.3 -12.9

ACAD Growth Metrics

    Its 3 year price growth rate is now at -26.16%.
  • Its 2 year cash and equivalents growth rate is now at 17.82%.
  • The 3 year net cashflow from operations growth rate now stands at 23.91%.
Over the past 33 months, ACAD's revenue has gone up $212,080,000.

The table below shows ACAD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 512.401 -129.638 -204.618
2022-03-31 493.059 -141.84 -214.478
2021-12-31 484.145 -125.66 -167.87
2021-09-30 474.394 -130.028 -191.536
2021-06-30 463.359 -135.757 -261.739
2021-03-31 458.241 -147.313 -260.009

ACAD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ACAD has a Quality Grade of C, ranking ahead of 66.5% of graded US stocks.
  • ACAD's asset turnover comes in at 0.606 -- ranking 51st of 682 Pharmaceutical Products stocks.
  • AKBA, PBYI, and DRRX are the stocks whose asset turnover ratios are most correlated with ACAD.

The table below shows ACAD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.606 0.980 -0.702
2021-03-31 0.593 0.979 -0.724
2020-12-31 0.573 0.977 -0.744
2020-09-30 0.543 0.974 -0.652
2020-06-30 0.515 0.972 -0.541
2020-03-31 0.531 0.969 -0.585

ACAD Price Target

For more insight on analysts targets of ACAD, see our ACAD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.53 Average Broker Recommendation 1.83 (Hold)

ACAD Stock Price Chart Interactive Chart >

Price chart for ACAD

ACAD Price/Volume Stats

Current price $17.19 52-week high $28.06
Prev. close $16.85 52-week low $12.24
Day low $16.80 Volume 176,563
Day high $17.32 Avg. volume 1,934,101
50-day MA $15.79 Dividend yield N/A
200-day MA $20.18 Market Cap 2.78B

ACADIA Pharmaceuticals Inc. (ACAD) Company Bio

Acadia Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. The firm aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia. The company was founded in 1993 by Mark Brann, PhD., a professor at the University of Vermont, under the name Receptor Technologies. By 1997, the company established its headquarters in San Diego, California and changed its name to Acadia Pharmaceuticals Inc and currently employs over 400 people. Since 2015, Stephen R. Davis serves as Acadia’s Chief Executive Officer and member of the board of directors. Competition for Acadia includes Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, and off-label branded and generic antipsychotics.

ACAD Latest News Stream

Event/Time News Detail
Loading, please wait...

ACAD Latest Social Stream

Loading social stream, please wait...

View Full ACAD Social Stream

Latest ACAD News From Around the Web

Below are the latest news stories about ACADIA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ACAD as an investment opportunity.

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

SAN DIEGO, September 01, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:

Yahoo | September 1, 2022

Wall Street Analysts Believe Acadia (ACAD) Could Rally 26%: Here's is How to Trade

The mean of analysts' price targets for Acadia (ACAD) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | August 30, 2022

Acadia (ACAD) Upgraded to Buy: What Does It Mean for the Stock?

Acadia (ACAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | August 26, 2022

ACADIA Pharmaceuticals (ACAD) Receives a Hold from Goldman Sachs

In a report released today, Salveen Richter from Goldman Sachs maintained a Hold rating on ACADIA Pharmaceuticals (ACAD - Research Report), with a price target of $15.00. The company's shares closed yesterday at $16.62.Richter covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Bluebird Bio, and Crispr Therapeutics AG. According to TipRanks, Richter has an average return of 30.3% and a 55.26% success rate on recommended stocks. In addition to Goldman Sachs, ACADIA Pharmaceuticals also received a Hold from Citigroup's Neena Bitritto-Garg in a report issued today. However, on the same day, JMP Securities reiterated a Buy rating on ACADIA Pharmaceuticals (NASDAQ: ACAD).

Howard Kim on TipRanks | August 9, 2022

ACADIA Pharmaceuticals (ACAD) Gets a Hold from Mizuho Securities

In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on ACADIA Pharmaceuticals (ACAD - Research Report), with a price target of $19.00. The company's shares closed yesterday at $16.62.According to TipRanks, Ear is a 4-star analyst with an average return of 14.7% and a 60.71% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, ACADIA Pharmaceuticals, and uniQure.In addition to Mizuho Securities, ACADIA Pharmaceuticals also received a Hold from Citigroup's Neena Bitritto-Garg in a report issued today. However, on the same day, JMP Securities reiterated a Buy rating on ACADIA Pharmaceuticals (NASDAQ: ACAD).

Brian Anderson on TipRanks | August 9, 2022

Read More 'ACAD' Stories Here

ACAD Price Returns

1-mo 5.98%
3-mo 0.59%
6-mo -25.84%
1-year 3.99%
3-year -55.75%
5-year -53.45%
YTD -26.35%
2021 -56.34%
2020 24.96%
2019 164.56%
2018 -46.30%
2017 4.40%

Continue Researching ACAD

Here are a few links from around the web to help you further your research on Acadia Pharmaceuticals Inc's stock as an investment opportunity:

Acadia Pharmaceuticals Inc (ACAD) Stock Price | Nasdaq
Acadia Pharmaceuticals Inc (ACAD) Stock Quote, History and News - Yahoo Finance
Acadia Pharmaceuticals Inc (ACAD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7715 seconds.